Brind.

AbbVie and Genmab pipeline updates and regulatory engagement

Steady: 0 in the last 7 days Updated oct 7

The latest in this situation

How it started

AbbVie, Genmab, and Sarah Cannon Research Institute announced the joint development of Epkinly for DLBCL treatment.

7 reports, 7 independent, last reported Oct 6. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 7 independent outlets

AbbVie, Genmab, and Sarah Cannon Research Institute announced the joint development of Epkinly for DLBCL treatment.

Who's involved

What this event is mainly about

AbbVie Genmab Sarah Cannon Research Institute

How it developed

Newest first. Tap a step to see who reported it.

Oct 6Stock price increased following the combination treatment announcement.1 source
- businesstimes.com.sg
Oct 6Phase 3 trial results for Epkinly were co-announced by the companies.1 source
- curetoday.com
Oct 5Trial results released for the joint development of Epkinly for DLBCL treatment.1 source
- onclive.com
Jun 29AbbVie and Genmab will engage global regulatory authorities regarding their joint development efforts.Sub-event
Sep 4Joint development of Epkinly for DLBCL treatment announced.1 source
- Clinical Trials Arena

Keep exploring

The entities involved

AbbVie
pharmaceutical company
- AbbVie and others are managing drug exclusivity, seeking next-gen immunology pipeline growth, and competing for market share.Thu 23:18
- AbbVie is developing ABBV-466, a potential successor to Skyrizi, whose patents may expire by 2033.Thu 23:18
Genmab
Danish healthcare company
- Truist Financial started coverage on Genmab shares, and TD Cowen raised rating and price target for the company, which trades on Nasdaq.00:48
- BioNTech announced new partnerships with Genmab, Pfizer, Bristol-Myers Squibb, and Genentech.Tue 13:29
Sarah Cannon Research Institute
research institute in Nashville, Tennessee, USA

Nothing else this week.

Coverage

Newest first; wire copies grouped

Oct 6businesstimes.com.sg
Oct 6curetoday.com
Oct 5investors.com
Oct 5onclive.com
Sep 4Clinical Trials ArenaAbbVie and Genmab’s Epkinly shows outpatient viability in Phase II trial AbbVie and Genmab’s subcutaneous Epkinly (epcoritamab) has proved to be viable as an outpatient treatment in a Phase II trial.
Aug 22ZacksABBV's Improving Oncology Sales Poise It Well for Long-Term Growth AbbVie ABBV is known for its strong immunology franchise comprising blockbuster drugs like Skyrizi, Rinvoq and Humira. However, AbbV
Aug 8Pharmaceutical TechnologyEpkinly breaks ground in Phase III FL trial Genmab and AbbVie’s subcutaneous bispecific antibody Epkinly (epcoritamab) has met its dual primary endpoints as a second-line combination therapy in relap